Neuronox
Phase 3Small molecule
Neuronox is one of 41 small molecule programs targeting Dystonia. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Overactive Bladder
#DrugCompanyPhaseTrials
1Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Botox
AbbViePhase 3
GSK1358820
GSKPhase 3
Tolterodine PR
PfizerPhase 3
Oxybutynin Chloride
Mylan Pharmaceuticals IncPhase 3
Vesicare
AstellasPhase 3
YM178
AstellasPhase 3
SPM 907
PfizerPhase 3
Onabotulinumtoxina 100 UNT
SStanford University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dystonia2 trials
Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia
Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 3·NCT03805152·52 enrolled
Neubotulinum Toxin Injection in Cerivical Dystonia
Completed·DDepartment of Medical Services Ministry of Public Health of Thailand·Phase 3·NCT04582929·50 enrolled
Moderate to Severe Glabellar Lines1 trial
Overactive Bladder1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Neuronox. EMBL-EBI & Wellcome Sanger Institute.
- [4]